Phuturdex › Diseases › Plasma cell neoplasm
Drugs in development · updated 30 October 2026
Plasma cell neoplasm: drugs in development
As of 30 October 2026 there are 37 active clinical trials (recruiting or ongoing, phases I–III) on 45 drugs for plasma cell neoplasm. 10 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Immunoglobulins | II–III | 1 | NCT05678621 |
| HDP-101 | I–II | 2 | NCT04879043 |
| EtentamigABBV-383, TNB-383B | I–II | 1 | NCT07600151 |
| Nemtabrutinib | I–II | 1 | NCT03162536 |
| QLS4131 | II | 1 | NCT07751471 |
| Belamaf | I | 1 | NCT07831122 |
| Cevostamab | I | 1 | NCT07831122 |
| KTX-1001 | I | 1 | NCT05651932 |
| MezigdomideCC-92480 | I | 1 | NCT05651932 |
| OriCAR-017 | I | 1 | NCT06271252 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| DexamethasoneDexametasone, Dextenza | III | 16 | NCT06152575 |
| LenalidomideRevlimid, lenalinomide | III | 12 | NCT07649525 |
| BortezomibVelcade, Bortezomib Hospira® | III | 6 | NCT06152575 |
| CarfilzomibKitprozy®, Kyprolis® | III | 6 | NCT06152575 |
| DaratumumabDarzalex | III | 5 | NCT07649525 |
| PomalidomideImnovid, Pomalyst® | III | 4 | NCT06152575 |
| IsatuximabIsatuximab SAR650984, Sarclisa Escena® | III | 3 | NCT04751877 |
| Amoxicillinamoxycillin, Moxatag® | II–III | 2 | NCT07202091 |
| Clavulanic acid | II–III | 2 | NCT07202091 |
| ElotuzumabEmpliciti® | III | 2 | NCT06152575 |
| ElranatamabElrantamab, Elrexfio® | III | 2 | NCT06152575 |
| SulfamethoxazoleGantanol®, Gantanol-Ds® | II–III | 2 | NCT07202052 |
| TrimethoprimPrimsol®, Trimpex 200® | II–III | 2 | NCT07202052 |
| Amoxi ClavulanateAmoxicillin clavulanic acid, Augmentin | II–III | 1 | NCT07202052 |
| CiprofloxacinOtiprio®, Cetraxal® | II–III | 1 | NCT05678621 |
Sorted by most advanced phase and number of active trials. Showing 15 of 35 drugs.
All 45 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Multiple myeloma 272 drugs
- Waldenstrom Macroglobulinemia 51 drugs
- Lymphoma 252 drugs
- Hematologic neoplasm 216 drugs
- Non-Hodgkin lymphoma 269 drugs
- Immunoglobulin Light-chain Amyloidosis 27 drugs
- Chronic lymphocytic leukemia 137 drugs
- Follicular lymphoma 144 drugs
- Lymphoma, B-Cell, Marginal Zone 86 drugs
- Neoplasm 671 drugs
- Mantle cell lymphoma 108 drugs
- Myelodysplastic Syndromes 203 drugs
Broader categories
- Neoplasm 671 drugs
- Immune System Diseases 54 drugs
- Lymphoproliferative disorders 51 drugs
- Immunoproliferative disorder 16 drugs
- Hematologic Diseases 57 drugs
- Vascular disease 16 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D054219 “Neoplasms, Plasma Cell”.